Members of Congress ask the FDA for documents relating to Aduhelm's controversial approval; outside experts will advise the FDA on booster shots; nursing shortages intensify.
Members of Congress have requested documents from the FDA related to its controversial approval of Biogen’s Alzheimer disease drug Aduhelm, STAT reported. The 2 panels, who had previously requested documents from Biogen, sent the request to acting FDA Commissioner Janet Woodcock, MD, marking the first public request by Congressional investigators to the agency. The requests come as previous reporting revealed Biogen had an off-the-books meeting with an FDA official prior to Aduhelm’s approval. The data requested touches on several of the drug’s controversies, including information as to why Aduhelm’s original indication was broader than populations studied in clinical trials.
On September 17, a group of outside advisors will meet with the FDA to discuss the need, or lack thereof, for COVID-19 booster shots, The Washington Post reported. The meeting is slated to take place 3 days prior to the original date the agency said Americans will become eligible to receive the booster shots. The meeting will be public and is expected to grant more clarity to the recommendations, which have been seen as unnecessary by some. It will also focus on data provided by Pfizer/BioNTech, although the panel’s recommendations are not binding. Some have criticized the United States’ decision to administer boosters to its own population while much of the world’s population has yet to receive an initial vaccine. Israel has already started administering boosters to its population.
Hospitals throughout the United States have been hit with acute nursing shortages as many leave the profession due to burnout, or turn to more lucrative opportunities with traveling agencies, according to the Associated Press. Although not a new problem wrought by the pandemic, the shortages have now lead to a crisis where some hospitals, strapped for cash, are unable to pay to get the help they need to treat COVID-19 patients. Mounting frustration among nurses tasked with treating unvaccinated patients and being harassed by members of their communities also contributes to the shortage.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More